Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profile

Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profile

Background: Brolucizumab is a new anti-vascular endothelial growth factor (anti-VEGF) in the treatment of neovascular age-related macular degeneration (nAMD) and idiopathic polypoidal choroidal vasculopathy (IPCV). Materials and Methods: A retrospective, consecutive, interventional study was conduct...

Full description

Bibliographic Details
Main Authors: Supriya Dabir, Arthi Mohankumar, Manoj G Khatri, Mohan Rajan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2024-01-01
Series:Indian Journal of Ophthalmology
Subjects:
age-related macular degeneration
anti-vascular endothelial growth factor
brolucizumab
choroidal neovascular membrane
idiopathic polypoidal choroidal vasculopathy
intraretinal fluid
pigment epithelial detachment
subretinal fluid
subretinal hyperreflective membrane
Online Access:http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=13;spage=33;epage=36;aulast=Dabir

Internet

http://www.ijo.in/article.asp?issn=0301-4738;year=2024;volume=72;issue=13;spage=33;epage=36;aulast=Dabir

Similar Items